Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with adbelimumab and apatinib for unresectable advanced hepatocellular carcinoma
ChiCTR2300078210Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: 6-month progression-free survival rate. Started Nov 2023; status: recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300078210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078210.